Subscription of new shares under general mandate
Filed with HKEX · Stock code 2126 · · 12 pages · English
Summary by 6ix AI
JW (Cayman) Therapeutics Co. Ltd. has announced a subscription agreement to issue new shares under a general mandate, involving two institutional investors subscribing for a significant number of shares at a specified price. The total gross proceeds from this subscription are expected to be substantial, with net proceeds estimated after deducting related expenses. The company plans to use the proceeds for research and development of its CAR-T pipeline and to enhance its manufacturing capabilities. Completion of the subscription is subject to certain conditions being met, and shareholders are advised to exercise caution in their dealings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
JW (Cayman) Therapeutics Co. Ltd. on 6ix
Earlier from JW (Cayman) Therapeutics
- Inside information - investor presentation on inclusion of CARTEYVA in NRDL and business update
- Inside information - inclusion of Carteyva (relmacabtagene autoleucel injection) in the national reimbursement drug list
- Very substantial disposal in relation to the license and assignment agreement
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow JW (Cayman) Therapeutics into a list and get an email when it puts out news.
Follow JW (Cayman) Therapeutics